The Anti-Longevity PlaybookGet the Playbook
Evidence Review
Peptides (General)
Verdict
Insufficient DataEvidence Tier
D
Insufficient evidence
Human Studies
Varies — mostly minimal
Typical Cost
$100-400/mo
Most commercially available peptides — including BPC-157, TB-500, and various GH secretagogues — lack adequate human safety or efficacy data. The peptide market operates largely outside FDA oversight, with purity, dosing, and contamination as ongoing concerns. Some peptides show promise in animal models, but the leap from rodent data to human longevity claims is not supported.
The full evidence review — including which peptides have any human data at all and why the market is called the Wild West — is in Section 4 (Peptides: The Wild West) of The Anti-Longevity Playbook.
Reviewed by Dr. Ramy Khalil, MD · Double Board-Certified Internal Medicine · Last updated March 2026
Are longevity peptides backed by evidence?
Most commercial peptides lack adequate human safety or efficacy data. The market operates largely outside FDA oversight, with purity and contamination concerns.
Free Chapter
Want the full picture?
Start with a free chapter.
Read the first chapter of The Anti-Longevity Playbook free — including the intervention with stronger mortality data than Peptides.
More from Peptides: The Wild West
Browse All Evidence Reviews
30+ longevity interventions reviewed by a physician against the primary literature.
ExerciseStatinsApoB TestingNMNNMN vs. NR — Which Is Better?ResveratrolRapamycinMetformin for LongevityBPC-157PeptidesCold Plunge / Cold ExposureSaunaSleepTestosterone Replacement TherapyGrowth HormoneContinuous Glucose MonitorFull-Body MRI ScreeningBiological Age TestsSemaglutideTirzepatideIntermittent FastingCaloric RestrictionBerberineOmega-3 Fatty AcidsVitamin DMagnesiumCoQ10SpermidineCreatineSocial ConnectionAlcohol